VRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-05), Verona Pharma's share price is $53.92. Verona Pharma's Book Value per Share for the quarter that ended in Dec. 2024 was $2.42. Hence, Verona Pharma's PB Ratio of today is 22.31.
The historical rank and industry rank for Verona Pharma's PB Ratio or its related term are showing as below:
During the past 13 years, Verona Pharma's highest PB Ratio was 28.96. The lowest was 1.59. And the median was 5.58.
During the past 12 months, Verona Pharma's average Book Value Per Share Growth Rate was -22.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -0.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -3.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -9.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Verona Pharma was 253.40% per year. The lowest was -27.10% per year. And the median was -2.20% per year.
The historical data trend for Verona Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verona Pharma Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
2.19 | 2.73 | 8.59 | 6.41 | 19.21 |
Verona Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6.41 | 5.79 | 6.97 | 18.04 | 19.21 |
For the Biotechnology subindustry, Verona Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Verona Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Verona Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Verona Pharma's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2024) |
= | 53.92 | / | 2.417 | |
= | 22.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Verona Pharma (NAS:VRNA) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Verona Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kathleen A. Rickard | officer: Chief Medical Officer | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Mark W Hahn | officer: Chief Financial Officer | 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517 |
David Zaccardelli | director, officer: President and CEO | 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069 |
David R Ebsworth | director | C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Christina Ackermann | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Martin Edwards | director | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Claire Poll | officer: General Counsel | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Rishi Gupta | director, 10 percent owner | C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Access Industries Holdings Llc | 10 percent owner | C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019 |
Ai Biotechnology Llc | 10 percent owner | C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Access Industries Management, Llc | 10 percent owner | 730 FIFTH AVENUE, NEW YORK NY 10019 |
Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
James Aloysius Brady | director | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
Lisa Deschamps | director | C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE |
From GuruFocus
By GuruFocus News • 11-14-2024
By GuruFocus News • 11-27-2024
By GuruFocus News • 11-08-2024
By Marketwired • 01-07-2025
By GuruFocus News • 11-14-2024
By GuruFocus News • 11-15-2024
By Marketwired • 11-19-2024
By GuruFocus News • 02-28-2025
By GuruFocus News • 11-06-2024
By Marketwired • 02-27-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.